Anteris Technologies Global Corp. aims to raise $75 million in an IPO for aortic stenosis treatment development in a growing ...

A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development ...

Edwards Lifesciences (NYSE:EW) today announced its plans for significant growth as a purely structural heart company in 2025.

Abbott has commenced the first subject procedures with its transcatheter aortic valve implantation (TAVI) system to treat ...

which is anticipated to offer fresh insights for global implanters treating symptomatic severe aortic stenosis (SASS). The ...

A recent study has revealed a strong link between insulin resistance and an increased risk of aortic stenosis (AS), a ...

Insulin resistance can increase the risk of aortic stenosis -- a common heart valve disease, in men over the age of 45, finds ...

In the CONDUCT-TAVI study, the use of a self-expanding valve was not associated with an increased risk of pacemaker.

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, ...

Insulin resistance associated with prediabetes appears to raise a person’s risk of a common and serious heart valve ...

Edwards Lifesciences (EW) reaffirmed original 2024 total company constant currency sales growth guidance of 8% to 10%. The company is ...

FY24 consensus $5.83B. “It is an exciting day for Edwards as we share our vision for 2025 and how our talented team and focus in structural ...